Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
20. August 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Aug 20, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced...
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
12. Juni 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jun 12, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced...
Marina Biotech Receives Decision to Grant Japanese Patent for Its SMARTICLES Nucleic Acid Delivery Technology
05. Juni 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jun 5, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that...
Marina Biotech to Present at the LD Micro Invitational 2014
28. Mai 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - May 28, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that...
Marina Biotech Provides Organizational Update
14. Mai 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - May 14, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today provided an...
Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded Nucleic Acids to Tumors
06. Mai 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - May 6, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, presented data from...
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases
02. April 2014 09:08 ET
|
Marina Biotech, Inc.
PRINCETON, NJ and REHOVOT, ISRAEL and BOSTON, MA--(Marketwired - Apr 2, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and...
Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
11. März 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Mar 11, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today...
Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology
27. Februar 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Feb 27, 2014) - Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced...
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note
24. Februar 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Feb 24, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today...